Detail akcie Ironwood Pharma online

Business Summary: Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ironwood Pharmaceuticals, Inc. revenues decreased 5% to $248.4M. Net income totaled $26.3M vs. loss of $1.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects human therapeutics. segment income increase of 49% to $91.7M.